Sandoz Malaysia Announces partnership to expand patient access to biosimilars

Partnership reflects shared commitment to support a high-quality, affordable and sustainable healthcare system in Malaysia

Kuala Lumpur, May 8, 2026 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordablemedicines, today entered into a Memorandum of Understanding (MoU) with Sunway Medical Centre to enhance patient education, expand understanding and adoption of biosimilars, and support clinical excellence in lymphoma care across Malaysia.

In Malaysia, access to biologic therapies remains uneven due to awareness gaps and system constraints – despite a significant disease burden. Non‑Hodgkin’s lymphoma alone is among the country’s most common cancers, with over 2,000 new patients diagnosed each year, many presenting at advanced stages where biologic therapies form an essential part of treatment. For many patients, however, sustaining or even initiating treatment remains challenging.

The MoU, effective until 31 December 2026, outlines a collaboration to build understanding and confidencein biosimilars among healthcare professionals, patients and the public, beginning with initiatives focused on lymphoma care. Through 2026, both parties will implement initiatives including patient engagement and support sessions, educational content development, public awareness programmes aligned with World Blood Cancer Awareness Month, and clinical engagement through medical symposia.

Sandoz Malaysia

Christine Chong, Country Head, Sandoz Malaysia, Singapore and Brunei, said: “Lymphoma is an area where biologic therapies are critical to patient outcomes, yet many patients face challenges accessing or sustaining treatment. Biosimilars offer the same clinical outcomes as reference biologics, with no meaningful differences in safety or effectiveness, while helping to reduce access barriers and improve system efficiency.

However, access is not only about availability – it depends on awareness, understanding and confidence among healthcare professionals and patients. Sunway’s leadership in clinical excellence and patient engagement makes them a highly-valued partner in improving lymphoma care and advancing broader understanding and confidence in biosimilars in Malaysia.”

Dr Seow Vei Ken, CEO of Sunway Medical Centre, said: “Collaborations with partners like Sandoz is essential for hospitals such as ours, as they bring global expertise and resources that help us stay at the forefront of medical innovation. By working together, we can ensure our patients have access to the latest advancements, such as biosimilars, which represent significant progress in effective treatment options.”

“Through this partnership, we are committed to providing education and outreach that equips our community with the knowledge and confidence to embrace new therapies. Our goal is to deliver care to more patients, while supporting the sustainable advancement of healthcare in Malaysia.”

On biosimilars

Globally, biosimilars have been widely adopted as part of efforts to improve access to advanced therapies, contributing to earlier treatment, better continuity of care and long‑term healthcare sustainability when supported by strong regulation and education. With more biologic medicines losing exclusivity in the coming years, Malaysia has an important opportunity to realise similar system‑level benefits through responsible adoption and collaboration across the healthcare ecosystem.

This partnership reflects the long‑standing commitment of Sandoz to expanding access to high‑quality and timely treatnebt through science-led collaboration.

In 2026, as Sandoz marks 140 years of global heritage as well as 20 years since pioneering the world’s first biosimilar, the company continues to draw on decades of scientific expertise to help more patients benefit from innovation and to support more sustainable healthcare systems worldwide.

#businessnews